GP
SPRO icon

GSK plc’s Spero Therapeutics SPRO Stock Holding History

GSK plc’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Hold
9,190,606
– – 3.37% 8
2026
Q1 		$21.5M Hold
9,190,606
– – 3.59% 8
2025
Q4 		$21.4M Buy
+9,190,606
New +$21.3M 2.68% 8

Other funds holding SPRO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GSK plc's SPRO Position: Q2 2026 in Review

GSK plc held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 9,190,606 shares worth $20.3M. The position accounts for 3.37% of the portfolio, ranked #8.

GSK plc first reported a position in SPRO in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.5M in Q1 2026. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • GSK plc held 9,190,606 shares of Spero Therapeutics worth $20.3M as of Q2 2026.
  • GSK plc left its Spero Therapeutics share count unchanged in Q2 2026.
  • Spero Therapeutics made up 3.37% of GSK plc's portfolio in Q2 2026, its #8 holding.
  • GSK plc first reported a position in Spero Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GSK plc's Spero Therapeutics position peaked at $21.5M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.